Interface Biologics Inc.
Rich Sullivan, President and CEO; or Mark Steedman, Director of Business Development
P 416.673.8170
E Rich Sullivan rsullivan@interfacebiologics.com ; or Mark Steedman msteedman@interfacebiologics.com
W www.interfacebiologics.com
Interface Biologics is a therapeutic biomaterials company focused on producing the next generation of smart, implantable, bioresorbable medical devices for use in cardiovascular, urogenital and musculoskeletal disease areas. The company’s comprehensive understanding of material structure and host response allows its materials to respond to inflammation, deliver a therapeutic payload, and be completely resorbed by the body.
Our goal is to continuously design innovative biomaterials that will bring about the delivery of successful health care products to world markets. This is being achieved through the application of novel polymer technologies that will increase blood and tissue compatibility, establish the timely release of drugs in vivo, and stimulate tissue regeneration for a broad–spectrum of biomaterials and devices including catheters, wound dressings and vascular stents.
BROWSE PAGES
- Ambit Biosciences
- AXS Biomedical Animation Studio
- BioSign Technologies
- Constab Pharmaceutical Inc.
- Clera Inc.
- Diagnostic Systems Laboratories
- Interface Biologics Inc.
- Invisage Technologies Inc.
- In Vitro Drug Safety and Biotechnology
- Kanata Chemical Technologies
- Larial Proteomics Inc.
- Matregen
- OCBN
- Octopz
- Pro Lab Developments
- Receptor Therapeutics Inc.
- Skymeter Corporation
- Space Quest
- YYZ Blue Sky Capital Corporation
